Parkinson's biomarker hunt: sargramostim trial seeks clues in immune cells
NCT ID NCT05677633
First seen Nov 05, 2025 · Last updated May 15, 2026 · Updated 27 times
Summary
This early-phase study tested a drug called sargramostim (Leukine) in 11 people with Parkinson's disease to see if it is safe and to find biological markers (biomarkers) in immune cells that could show how the drug works. Participants received the drug weekly for 48 weeks and had regular blood tests and leukapheresis to collect immune cells. The goal was to understand immune changes linked to Parkinson's, not to cure or treat symptoms directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE AND PARKINSONISM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
Conditions
Explore the condition pages connected to this study.